Annovis Bio Inc. (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company focused on neurodegenerative diseases, has announced it will host a corporate update webinar on Sept. 2, 2026, at 4 p.m. EDT. The event will feature Founder, President and CEO Maria Maccecchini, Ph.D., who will discuss recent progress, ongoing clinical programs, and upcoming milestones. This announcement comes as the company prepares to release top-line data from its fully enrolled pivotal Phase 3 Alzheimer's disease (AD) trial, with regulatory submissions expected in 2027.
The webinar is particularly significant because it will provide investors and stakeholders with insights into the company's strategic direction and the potential of its lead drug candidate, buntanetap. Buntanetap, an investigational once-daily oral therapy, is designed to inhibit the translation of multiple neurotoxic proteins, including amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism. By addressing these underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients.
In addition to the Phase 3 AD trial, Annovis is planning to initiate an open-label study in October 2026 to generate long-term safety data for buntanetap in AD patients. The company is also advancing its Parkinson's disease (PD) program, with an open-label study currently underway and discussions ongoing regarding the initiation of a Parkinson's disease dementia program. These developments underscore Annovis's commitment to expanding its pipeline and addressing the significant unmet medical needs in neurodegenerative diseases.
The upcoming webinar and the company's clinical milestones are important for several reasons. First, the Phase 3 AD trial is a critical step toward potential approval of buntanetap, which could offer a new treatment option for the millions of patients suffering from Alzheimer's disease. Second, the expansion into Parkinson's disease and related dementias highlights the broad therapeutic potential of buntanetap, which may differentiate it from other treatments that target only one aspect of neurodegeneration. Third, the company's focus on long-term safety data through open-label studies demonstrates a commitment to understanding the full risk-benefit profile of its therapy.
Investors and industry observers will be watching the webinar closely for updates on trial enrollment, data timelines, and regulatory strategy. The company's ability to execute on these milestones could have a significant impact on its valuation and the future of neurodegenerative disease treatment. Annovis Bio is headquartered in Malvern, Pennsylvania, and its stock trades on the NYSE under the ticker symbol ANVS. For more information about the company and its programs, visit its website at annovisbio.com.
